{"meta":{"totalResults":1,"from":0},"results":[{"aliases":[{"type":"CodeName","name":"REGN7075"},{"type":"CodeName","name":"bsAb7075"},{"type":"Synonym","name":"EGFR x CD28 bispecific antibody REGN7075"},{"type":"CodeName","name":"REGN 7075"},{"type":"CodeName","name":"REGN-7075"}],"definition":{"html":"A bispecific antibody directed against both human epidermal growth factor receptor (EGFR) and the co-stimulatory T-cell-specific surface glycoprotein CD28, with potential immunostimulating and antineoplastic activities. Upon administration of marlotamig, this bispecific antibody binds to both CD28 on cytotoxic T lymphocytes (CTLs) and EGFR found on EGFR-expressing tumor cells. This activates and redirects CTLs to EGFR-expressing tumor cells, which may result in the CTL-mediated cell death of EGFR-expressing tumor cells. EGFR, a member of the epidermal growth factor receptor family, is overexpressed on various tumor cell types.","text":"A bispecific antibody directed against both human epidermal growth factor receptor (EGFR) and the co-stimulatory T-cell-specific surface glycoprotein CD28, with potential immunostimulating and antineoplastic activities. Upon administration of marlotamig, this bispecific antibody binds to both CD28 on cytotoxic T lymphocytes (CTLs) and EGFR found on EGFR-expressing tumor cells. This activates and redirects CTLs to EGFR-expressing tumor cells, which may result in the CTL-mediated cell death of EGFR-expressing tumor cells. EGFR, a member of the epidermal growth factor receptor family, is overexpressed on various tumor cell types."},"drugInfoSummaryLink":null,"nciConceptId":"C178284","nciConceptName":"Marlotamig","termId":804713,"name":"marlotamig","firstLetter":"m","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"marlotamig"}],"links":null}